Tower Bridge Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Tower Bridge Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,000	Closed	-$315K	–	226
2023 Q1	$315K	Hold	1,000	–	–	0.03%	204
2022 Q4	$289K	Hold	1,000	–	–	0.02%	211
2022 Q3	$290K	Hold	1,000	–	–	0.03%	202
2022 Q2	$282K	Hold	1,000	–	–	0.02%	213
2022 Q1	$261K	Hold	1,000	–	–	0.02%	230
2021 Q4	$220K	Buy	+1,000	New	+$194K	0.01%	247
2021 Q3	–	Sell	-1,000	Closed	-$202K	–	266
2021 Q2	$202K	Hold	1,000	–	–	0.01%	244
2021 Q1	$215K	Hold	1,000	–	–	0.02%	221
2020 Q4	$236K	Hold	1,000	–	–	0.02%	212
2020 Q3	$272K	Hold	1,000	–	–	0.03%	166
2020 Q2	$290K	Hold	1,000	–	–	0.03%	158
2020 Q1	$238K	Hold	1,000	–	–	0.03%	160
2019 Q4	$219K	Hold	1,000	–	–	0.02%	192
2019 Q3	$201K	Buy	+1,000	New	+$177K	0.02%	201
2017 Q2	–	Sell	-2,400	Closed	-$262K	–	216
2017 Q1	$262K	Sell	2,400 -500	-17%	-$44K	0.03%	182
2016 Q4	$214K	Sell	2,900 -700	-19%	-$57K	0.03%	200
2016 Q3	$314K	Hold	3,600	–	–	0.04%	169
2016 Q2	$310K	Sell	3,600 -1,000	-22%	-$86.4K	0.04%	167
2016 Q1	$366K	Hold	4,600	–	–	0.05%	160
2015 Q4	$579K	Hold	4,600	–	–	0.08%	138
2015 Q3	$479K	Hold	4,600	–	–	0.07%	146
2015 Q2	$568K	Hold	4,600	–	–	0.07%	132
2015 Q1	$543K	Hold	4,600	–	–	0.07%	138
2014 Q4	$546K	Hold	4,600	–	–	0.07%	140
2014 Q3	$517K	Hold	4,600	–	–	0.07%	141
2014 Q2	$436K	Hold	4,600	–	–	0.05%	149
2014 Q1	$325K	Hold	4,600	–	–	0.04%	163
2013 Q4	$342K	Hold	4,600	–	–	0.04%	159
2013 Q3	$349K	Hold	4,600	–	–	0.05%	150
2013 Q2	$368K	Buy	+4,600	New	+$339K	0.05%	151

Other funds holding VRTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Tower Bridge Advisors's VRTX Position: Q2 2023 in Review

Tower Bridge Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q2 2023, closing a stake of 1,000 shares — an estimated $315K sold.

Tower Bridge Advisors first reported a position in VRTX in Q2 2013 and held it in 30 quarters. The position peaked at $579K in Q4 2015. 1,286 funds tracked by Wall St. Rank hold VRTX as of Q2 2023.

Tower Bridge Advisors reported no remaining Vertex Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Tower Bridge Advisors sold 1,000 Vertex Pharmaceuticals shares in Q2 2023, an estimated $315K.
Tower Bridge Advisors first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 30 quarters.
Tower Bridge Advisors's Vertex Pharmaceuticals position peaked at $579K in Q4 2015.
1,286 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2023.

Based on Tower Bridge Advisors's 13F filing for Q2 2023, filed 20 Jul 2023.